

Darran P O'connor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6623293/publications.pdf>

Version: 2024-02-01

60
papers

3,291
citations

136950

32
h-index

149698

56
g-index

61
all docs

61
docs citations

61
times ranked

6915
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 807-818.	7.0	34
2	Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors. <i>European Journal of Cancer</i> , 2021, 152, 78-89.	2.8	2
3	FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. <i>British Journal of Cancer</i> , 2020, 122, 361-371.	6.4	38
4	A Functional Genomic Screen Identifies the Deubiquitinase USP11 as a Novel Transcriptional Regulator of ER \pm in Breast Cancer. <i>Cancer Research</i> , 2020, 80, 5076-5088.	0.9	18
5	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. <i>Scientific Reports</i> , 2020, 10, 9778.	3.3	5
6	Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. <i>Journal of the National Cancer Institute</i> , 2019, 111, 388-398.	6.3	81
7	BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7139-7150.	7.0	18
8	Dysregulated mitogen-activated protein kinase signalling as an oncogenic basis for clear cell sarcoma of the kidney. <i>Journal of Pathology</i> , 2018, 244, 334-345.	4.5	7
9	Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3692-3703.	7.0	13
10	Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. <i>Cancer Letters</i> , 2018, 414, 99-106.	7.2	48
11	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. <i>Journal of Clinical Oncology</i> , 2018, 36, 2052-2060.	1.6	26
12	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. <i>Nature Communications</i> , 2018, 9, 4112.	12.8	55
13	BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer. <i>Oncotarget</i> , 2018, 9, 15673-15690.	1.8	22
14	Vitamin D receptor as a target for breast cancer therapy. <i>Endocrine-Related Cancer</i> , 2017, 24, 181-195.	3.1	40
15	The Emerging Role of Non-traditional Ubiquitination in Oncogenic Pathways. <i>Journal of Biological Chemistry</i> , 2017, 292, 3543-3551.	3.4	41
16	Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2017, 77, 3834-3845.	0.9	79
17	Fam60a defines a variant Sin3a-Hdac complex in embryonic stem cells required for self-renewal. <i>EMBO Journal</i> , 2017, 36, 2216-2232.	7.8	45
18	Assessment of Significance of Novel Proteins in Breast Cancer Using Tissue Microarray Technology. <i>Methods in Molecular Biology</i> , 2017, 1501, 311-325.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?. <i>International Journal of Cancer</i> , 2017, 140, 234-246.	5.1	79
20	Postmortem Examination of an Aggressive Case of Medullary Thyroid Carcinoma Characterized by Catastrophic Genomic Abnormalities. <i>JCO Precision Oncology</i> , 2017, 1, 1-7.	3.0	1
21	Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer. <i>Oncotarget</i> , 2017, 8, 42949-42961.	1.8	42
22	Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach. <i>Oncotarget</i> , 2017, 8, 48126-48137.	1.8	12
23	Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. <i>Scientific Reports</i> , 2016, 6, 18517.	3.3	143
24	De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage III breast cancer. <i>British Journal of Cancer</i> , 2016, 115, 592-598.	6.4	16
25	RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw111.	6.3	11
26	Biosimilars: Extrapolation for oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 104, 131-137.	4.4	40
27	Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 541-551.	3.1	4
28	Monounsaturated Fatty Acid-Enriched High-Fat Diets Impede Adipose NLRP3 Inflammasome-Mediated IL-1 β Secretion and Insulin Resistance Despite Obesity. <i>Diabetes</i> , 2015, 64, 2116-2128.	0.6	229
29	FKBPL: a marker of good prognosis in breast cancer. <i>Oncotarget</i> , 2015, 6, 12209-12223.	1.8	13
30	Dynamic and influential interaction of cancer cells with normal epithelial cells in 3D culture. <i>Cancer Cell International</i> , 2014, 14, 108.	4.1	29
31	A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer. <i>Breast Cancer Research</i> , 2014, 16, 467.	5.0	11
32	Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer. <i>Breast Cancer Research</i> , 2014, 16, R79.	5.0	52
33	p53 as a target for the treatment of cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 1153-1160.	7.7	187
34	microRNAs: a new class of breast cancer biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 347-363.	3.1	36
35	miRNA Dysregulation in Breast Cancer. <i>Cancer Research</i> , 2013, 73, 6554-6562.	0.9	217
36	Ghrelin concentrations in maternal and cord blood of Type 1 diabetic and non-diabetic pregnancies at term. <i>Endocrine</i> , 2013, 43, 233-235.	2.3	7

#	ARTICLE	IF	CITATIONS
37	Identification of transcription factors associated with castration resistance: Is the serum responsive factor a potential therapeutic target?. <i>Prostate</i> , 2013, 73, 743-753.	2.3	18
38	miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential <i>In Vitro</i> . <i>Clinical Cancer Research</i> , 2012, 18, 6702-6713.	7.0	75
39	Maternal and fetal cocaine- and amphetamine-regulated transcript in diabetic and non-diabetic pregnancy. <i>Gynecological Endocrinology</i> , 2012, 28, 682-685.	1.7	3
40	The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ER α , and is an independent prognostic factor in node-negative breast cancer. <i>Oncogene</i> , 2012, 31, 3483-3494.	5.9	10
41	Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer. <i>Diagnostic Pathology</i> , 2012, 7, 115.	2.0	56
42	Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen. <i>Breast Cancer Research</i> , 2011, 13, R12.	5.0	22
43	SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas. <i>American Journal of Surgical Pathology</i> , 2011, 35, 937-948.	3.7	209
44	Identification of a myometrial molecular profile for dystocic labor. <i>BMC Pregnancy and Childbirth</i> , 2011, 11, 74.	2.4	12
45	Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. <i>Molecular Cancer</i> , 2011, 10, 126.	19.2	170
46	Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer. <i>BMC Cancer</i> , 2010, 10, 125.	2.6	39
47	Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer. <i>BMC Cancer</i> , 2010, 10, 639.	2.6	38
48	Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. <i>Nature Reviews Cancer</i> , 2010, 10, 605-617.	28.4	181
49	Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. <i>Journal of Translational Medicine</i> , 2010, 8, 78.	4.4	74
50	The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. <i>European Journal of Cancer</i> , 2009, 45, 1510-1517.	2.8	79
51	Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 2681-2689.	7.0	83
52	Breast cancer proteomics: clinical perspectives. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 209-219.	3.1	8
53	Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer. <i>Cellular and Molecular Life Sciences</i> , 2007, 64, 3159-3184.	5.4	86
54	Proteomic analysis of factors released from p21-overexpressing tumour cells. <i>Proteomics</i> , 2006, 6, 3739-3753.	2.2	12

#	ARTICLE	IF	CITATIONS
55	DNA damage-responsive acetylation of pRb regulates binding to E2F1. EMBO Reports, 2006, 7, 192-198.	4.5	59
56	Surface-induced changes in protein adsorption and implications for cellular phenotypic responses to surface interaction. Biomaterials, 2006, 27, 3096-3108.	11.4	208
57	Molecular basis of cell-biomaterial interaction: Insights gained from transcriptomic and proteomic studies. Biomaterials, 2006, 27, 5871-5882.	11.4	61
58	Functional interrogation of breast cancer: from models to drugs. Expert Opinion on Drug Discovery, 2006, 1, 569-584.	5.0	3
59	A new effector pathway links ATM kinase with the DNA damage response. Nature Cell Biology, 2004, 6, 968-976.	10.3	51
60	Altered p53 Expression in Benign and Malignant Skin Lesions From Renal Transplant Recipients and Immunocompetent Patients With Skin Cancer: Correlation With Human Papillomaviruses?. Diagnostic Molecular Pathology, 2001, 10, 190-199.	2.1	24